ASX:OPL

Opyl Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Opyl (ASX:OPL) Vs. 1ST, ALC, BNVIF, CNNA, CNONF, and DOCRF

Should you be buying OPL stock or one of its competitors? Companies in the industry of "health information services" are considered alternatives and competitors to Opyl, including 1st Group (1ST), Alcidion Group (ALC), Binovi Technologies (BNVIF), Cann American (CNNA), CannaOne Technologies (CNONF), and CloudMD Software & Services (DOCRF).

Opyl (ASX:OPL) and 1st Group (ASX:1ST) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Analyst Ratings

This is a summary of current ratings and recommmendations for Opyl and 1st Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Opyl0000N/A
1st Group0000N/A

Profitability

This table compares Opyl and 1st Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OpylN/AN/AN/A
1st GroupN/AN/AN/A

Valuation and Earnings

This table compares Opyl and 1st Group's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Opyl$741,494.000.00$-91,437.20A$0.00N/A
1st Group$5.11 million0.00$-4,246,169.92A($0.01)N/A

Opyl has higher earnings, but lower revenue than 1st Group.

Summary

Opyl beats 1st Group on 2 of the 3 factors compared between the two stocks.

Opyl (ASX:OPL) and Alcidion Group (ASX:ALC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Profitability

This table compares Opyl and Alcidion Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OpylN/AN/AN/A
Alcidion GroupN/AN/AN/A

Valuation and Earnings

This table compares Opyl and Alcidion Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Opyl$741,494.000.00$-91,437.20A$0.00N/A
Alcidion Group$21.55 million0.00$-2,972,082.05A$0.00N/A

Opyl has higher earnings, but lower revenue than Alcidion Group.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Opyl and Alcidion Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Opyl0000N/A
Alcidion Group0000N/A

Summary

Opyl beats Alcidion Group on 2 of the 3 factors compared between the two stocks.

Binovi Technologies (OTCMKTS:BNVIF) and Opyl (ASX:OPL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares Binovi Technologies and Opyl's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Binovi TechnologiesN/AN/AN/A
OpylN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Binovi Technologies and Opyl, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Binovi Technologies0000N/A
Opyl0000N/A

Valuation and Earnings

This table compares Binovi Technologies and Opyl's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Binovi TechnologiesN/AN/AN/AN/AN/A
Opyl$741,494.000.00$-91,437.20A$0.00N/A

Binovi Technologies has higher earnings, but lower revenue than Opyl.

Summary

Opyl beats Binovi Technologies on 1 of the 1 factors compared between the two stocks.

Opyl (ASX:OPL) and Cann American (CNSX:CNNA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Valuation & Earnings

This table compares Opyl and Cann American's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Opyl$741,494.000.00$-91,437.20A$0.00N/A
Cann AmericanN/AN/AN/AN/AN/A

Cann American has lower revenue, but higher earnings than Opyl.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Opyl and Cann American, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Opyl0000N/A
Cann American0000N/A

Profitability

This table compares Opyl and Cann American's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OpylN/AN/AN/A
Cann AmericanN/AN/AN/A

Summary

Opyl beats Cann American on 1 of the 1 factors compared between the two stocks.

Opyl (ASX:OPL) and CannaOne Technologies (OTCMKTS:CNONF) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Opyl and CannaOne Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Opyl0000N/A
CannaOne Technologies0000N/A

Earnings & Valuation

This table compares Opyl and CannaOne Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Opyl$741,494.000.00$-91,437.20A$0.00N/A
CannaOne TechnologiesN/AN/AN/AN/AN/A

CannaOne Technologies has lower revenue, but higher earnings than Opyl.

Profitability

This table compares Opyl and CannaOne Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OpylN/AN/AN/A
CannaOne TechnologiesN/AN/AN/A

Summary

Opyl beats CannaOne Technologies on 1 of the 1 factors compared between the two stocks.

CloudMD Software & Services (OTCMKTS:DOCRF) and Opyl (ASX:OPL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Earnings & Valuation

This table compares CloudMD Software & Services and Opyl's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CloudMD Software & ServicesN/AN/AN/AN/AN/A
Opyl$741,494.000.00$-91,437.20A$0.00N/A

CloudMD Software & Services has higher earnings, but lower revenue than Opyl.

Analyst Recommendations

This is a breakdown of current ratings for CloudMD Software & Services and Opyl, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CloudMD Software & Services00203.00
Opyl0000N/A

CloudMD Software & Services currently has a consensus price target of $3.3750, suggesting a potential upside of 117.74%.

Profitability

This table compares CloudMD Software & Services and Opyl's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CloudMD Software & ServicesN/AN/AN/A
OpylN/AN/AN/A


Opyl Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
1st Group logo
1ST
1st Group
0.5N/AN/A$0.00$5.11 million0.00High Trading Volume
Gap Up
ALC
Alcidion Group
0.5N/AN/A$0.00$21.55 million0.00High Trading Volume
Gap Up
Binovi Technologies logo
BNVIF
Binovi Technologies
0.0$0.05flat$0.00N/A0.00Gap Up
CNNA
Cann American
0.5N/AN/A$0.00N/A0.00High Trading Volume
CannaOne Technologies logo
CNONF
CannaOne Technologies
0.6$1.05flat$0.00N/A0.00
CloudMD Software & Services logo
DOCRF
CloudMD Software & Services
1.7$1.55flat$0.00N/A0.00Gap Up
DOC
CloudMD Software & Services
1.2$1.96flatC$0.00C$11.65 million-21.78
CGS
Cogstate
0.5N/AN/A$0.00$28.82 million0.00High Trading Volume
Gap Up
COO
Corum Group
0.5N/AN/A$0.00$12.27 million0.00High Trading Volume
EGF Theramed Health logo
EVAHF
EGF Theramed Health
0.0$0.10flat$0.00N/A0.00Gap Up
EMD
Emyria
0.6N/AN/A$0.00$1.73 million0.00High Trading Volume
Gap Up
EWLL
eWellness Healthcare
0.6$0.00flat$0.00N/A0.00
FORA
Forian
0.3$12.29flat$0.00N/A0.00
GLH
Global Health
0.5N/AN/A$0.00$6.77 million0.00High Trading Volume
Gap Up
ICS
ICS Global
0.9N/AN/A$0.00$6.08 million0.00High Trading Volume
Gap Up
JHL
Jayex Healthcare
0.7N/AN/A$0.00$6.61 million0.00High Trading Volume
Gap Up
M3 logo
MTHRF
M3
1.0$76.00flat$0.00N/A0.00
M7T
Mach7 Technologies
0.6N/AN/A$0.00$16.89 million0.00High Trading Volume
Gap Up
MDR
MedAdvisor
0.5N/AN/A$0.00$18.09 million0.00High Trading Volume
Gap Up
NEWUF
Newtopia
1.7$0.38flat$0.00N/A0.00
NHL
Novita Healthcare
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
ONE
Oneview Healthcare
0.5N/AN/A$0.00$7.10 million0.00High Trading Volume
PCK
PainChek
0.0N/AN/A$0.00$240,424.000.00High Trading Volume
PANHF
Ping An Healthcare and Technology
1.0$12.10flat$0.00N/A0.00
PKS
PKS
0.0N/AN/A$0.00$5.97 million0.00High Trading Volume
PME
Pro Medicus
0.7N/AN/A$0.00$59.12 million0.00High Trading Volume
Gap Up
Pro Medicus logo
PMCUF
Pro Medicus
0.5$35.85flat$0.00N/A0.00
RAP
ResApp Health
0.9N/AN/A$0.00$46,197.000.00High Trading Volume
Gap Up
CBIIF
Skylight Health Group
0.0$0.91flat$0.00N/A0.00High Trading Volume
News Coverage
TD1
TALi Digital
0.5N/AN/A$0.00$706,550.000.00High Trading Volume
UCBB
US-China Biomedical Technology
0.3$0.10flat$0.00N/A0.00
WELL Health Technologies logo
WLYYF
WELL Health Technologies
1.6$5.50flat$0.00N/A0.00News Coverage
ZMD
ZoomMed
0.4$0.02flatC$0.00C$10,000.00-1.36Gap Down
This page was last updated on 4/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.